In line with its mission to transform the lives of patients around the world through innovative medical solutions, Boston Scientific Corporation (NYSE: BSX) today announced the launch of AVVIGO™+ Multi-Modality Guidance System, a next-generation intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system with advanced software and hardware features designed to provide high-quality IVUS vessel imaging and physiology experience during percutaneous coronary intervention (PCI) procedures.
Key features of the AVVIGO™+ system include:
- Automates key procedural steps and provides precise vessel measurements through the use of artificial intelligence software called Automated Lesion Assessment. It is the first IVUS system that is AI enabled. Reduces procedure time significantly by acquiring IVUS images at a faster speed.
- Provides enhanced guidance by drawing a physiology graph that helps to provide a roadmap to treat the diseased coronary artery.
“We are pleased to introduce physicians in India to the next-generation AVVIGO™+ Multi-Modality Guidance System which provides fast, intuitive, and accurate vessel and lesion assessment capabilities for percutaneous coronary interventions,” said Madan R. Krishnan, vice president and managing director, India Subcontinent, Boston Scientific. “We believe this enhanced and automated tool will help them optimize these procedures to provide better outcomes for their patients with coronary artery disease.”
The fractional flow reserve (FFR) technology enables the system to assess the severity of coronary artery blockages inside the coronary arteries. It is a minimally invasive procedure that measures and analyzes the severity of coronary artery stenosis, with the help of pressure sensors, by comparing blood flow and pressure in the coronary arteries with and without a blockage.[1] These parameters help physicians assess the significance of coronary artery disease and make informed decisions about treatment options.
IVUS is a specialized diagnostic procedure that uses an ultrasound probe to create high-resolution images of the heart’s structures and function from inside the heart. Unlike traditional echocardiograms that use sound waves to produce images from outside the body, IVUS involves inserting a thin catheter with an ultrasound probe directly into the heart.
The AVVIGO™+ system received approval from the Central Drugs Standard Control Organization (CDSCO) in July 2024. Boston Scientific manufactures a wide variety of catheters for coronary, peripheral, and cardiac conditions. The recommended use of each of these catheters may vary depending on the location of the disease.
